Compare DexCom, Inc. (DXCM) vs Westinghouse Air Brake Technologies Corporation Common Stock (WAB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Westinghouse Air Brake Technologies Corporation Common Stock — how do they compare? DexCom, Inc. trades at $86 (market cap $31.51B), while Westinghouse Air Brake Technologies Corporation Common Stock trades at $283.97 (market cap $48.39B). The key difference: Westinghouse Air Brake Technologies Corporation Common Stock is the larger of the two by market cap, and Westinghouse Air Brake Technologies Corporation Common Stock pays a 0.43% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Westinghouse Air Brake Technologies Corporation Common Stock for 0 Days on average.
| DXCM | WAB | |
|---|---|---|
Market Cap | $31.51B | $48.39B |
Volume | 3,480,291 | 801,560 |
Sector | Health | Industrials |
52-Week High | $92.34 | $305.79 |
52-Week Low | $54.84 | $193.43 |
Typical Hold Time | 62 Days | 0 Days |
Enterprise Value | $30.96B | $54.29B |
Dividend Yield | — | 0.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $85.06, down 1.0% on the day, with a bullish technical signal and strong fundamental momentum. The stock is supported by consistent earnings beats, robust revenue growth from $4.0B in 2024 to $4.7B in 2025, and expanding net profit margins to 17.93%. Recent news highlights growth opportunities in Type 2 diabetes care and leadership appointments, reinforcing positive sentiment. Key resistance sits at $87, with immediate support at $85.
The outlook remains favorable given analyst consensus of a $96.14 price target and 80.77% buy ratings, though risks include competitive pressures and reimbursement challenges. Upside is driven by CGM adoption growth, while execution on guidance and market expansion are critical for sustained performance.
Wabtec (WAB) trades at $286.51, up 0.26% today, with a neutral technical signal. The company shows strong fundamentals, with Q2 2026 EPS of $2.76 beating estimates and revenue growth to $12.0B projected for 2026. A $700M+ African rail services deal and raised full-year guidance highlight positive business momentum. Key support rests at $284, with resistance at $288.
The outlook is positive, driven by earnings beats, margin expansion, and a robust backlog. Risks include premium valuation (P/E 38.56) and investing cash outflows. Analyst consensus is bullish with a $326.50 price target, suggesting ~14% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Westinghouse Air Brake Technologies Corporation Common Stock
Westinghouse Air Brake Technologies Corporation, known as Wabtec, provides equipment, systems, and services for the freight rail and passenger transit industries. Its Freight segment supplies locomotives, braking systems, and signaling technology, while its Transit segment supports passenger rail systems worldwide.
Read more on WAB →
